Depression is one of the most common mood disorders worldwide and can affect anyone regardless of age and sex. This brings us to fluoxetine – an antidepressant that has potential to be a cutting edge treatment for depression and other mental disorders.

This video covers topics of depression, general information regarding fluoxetine (e.g., side effects, dosage), as well as the biological mechanism of the fluoxetine and how it is used to combat depression.

[Please complete our feedback form]





References

Resources:

References:

  • Arroll, B., Macgillivray, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., & Crombie, I. (2005). Efficacy and Tolerability of Tricyclic Antidepressants and SSRIs Compared With Placebo for Treatment of Depression in Primary Care: A Meta-Analysis. The Annals of Family Medicine, 3(5), 449–456. https://doi.org/10.1370/afm.349
  • Brigitta, B. (2002). Pathophysiology of depression and mechanisms of treatment. Dialogues in Clinical Neuroscience, 4(1), 7–20.
  • Bromet, E., Andrade, L. H., et al. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine, 9(1), 90.
  • Depression. (n.d.). Retrieved October 29, 2020, from https://www.who.int/news-room/fact-sh...
  • Fava, M., Rosenbaum, J. F. et al. (2000). Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression. Journal of Affective Disorders, 59(2), 119–126.
  • Ferguson, J. M. (2001). SSRI Antidepressant Medications: Adverse Effects and Tolerability. The Primary Care Companion to The Journal of Clinical Psychiatry, 03(01), 22–27.
  • Furukawa, T. A., Cipriani, A., et al. (2019). Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis. The Lancet Psychiatry, 6(7), 601–609.
  • Goldman, L. (2019, November 22). Depression: What it is, symptoms, causes, treatment, types, and more (T. J. Legg, Ed.). Retrieved from https://www.medicalnewstoday.com/arti...
  • How SSRIs work. (n.d.). Retrieved October 1, 2020, from https://www.ocduk.org/overcoming-ocd/...
  • Lim, G. Y., Tam, W. W., Lu, Y., Ho, C. S., Zhang, M. W., & Ho, R. C. (2018). Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Scientific Reports, 8(1), 2861.
  • Rossi, A., Barraco, A., & Donda, P. (2004). Fluoxetine: A review on evidence based medicine. Annals of General Hospital Psychiatry, 3(1), 2.
  • Steffens, D., Krishnan, K., et al. (1997). Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. In Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination.
  • Wang, J., Wu, X., et al. (2017). Prevalence of depression and depressive symptoms among outpatients: A systematic review and meta-analysis. BMJ Open, 7(8), e017173.
  • Wenthur, C. J., Bennett, M. R., & Lindsley, C. W. (2014). Classics in Chemical Neuroscience: Fluoxetine (Prozac). ACS Chemical Neuroscience, 5(1), 14–23.
Accessibility for Ontarians With Disabilities Act (AODA)

 

The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at fhsweb@mcmaster.ca.